Form 8-K · Current Report · Filed 2024-02-28
Natera Reports Strong Financial Results for Q4 and Full Year 2023
Natera, Inc. reported significant revenue growth for the fourth quarter and full year 2023, with total revenues increasing by 43.2% and 32.0% respectively. The company processed more tests and recognized revenue on more tests, leading to improved gross margins. Natera also provided financial guidance for 2024, anticipating total revenue between $1.32 billion and $1.35 billion and a gross margin of 50% to 53%.
- Filer
- Natera Inc. NTRA · NASDAQ
- Filed
- Accession
- 0001104659-24-028724
- CIK
- 0001604821
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$76.16
Next session
+13.6%
Since filing
+251.6%
Latest close
$267.76
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from NTRA reporting the same item, with the next session's move:
Exhibits (2)
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Never miss another NTRA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.